Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraventricular Omburtamab-based Radioimmunotherapy for Recurrent Medulloblastoma and Ependymoma
NCT04743661Phase 2Active, not recruiting
- Sponsor
- Pediatric Brain Tumor Consortium
- Start
- Apr 2022
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of 131I-omburtamab in medulloblastoma and ependymoma (2 arms), sponsored by Pediatric Brain Tumor Consortium. Primary endpoints: Event-Free Survival at 2 years and Feasibility Criteria Met at 3 months. Started Apr 2022; status: active, not recruiting.
02
Drugs
131I-omburtamab
03
Conditions
medulloblastomaependymoma
Beyond the preview
Go deeper on NCT04743661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04743661.